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BRCA1 is a crucial human breast and ovarian cancer tumor suppressor gene. The article by Drost et al. in this
issue of Cancer Cell together with a recent paper in Science now provide a clearer picture of how this large
and complex protein suppresses tumorigenesis.Breast and ovarian cancer are major
causes of mortality and morbidity in the
developed world. Up to 10% of all breast
cancers are due to the inheritance of
germline mutations in two breast cancer
susceptibility loci (BRCA1 and BRCA2).
In fact, mutations in BRCA1 account for
up to 80% of families with breast and
ovarian cancer predisposition and there-
fore pose a significant burden to human
health. The BRCA1 gene encodes a large
polypeptide that interacts with its consti-
tutive binding partner BARD1. There is
a body of evidence indicating that the
BRCA1-BARD1 heterodimer is a crucial
regulator of the cellular response to
DNA damage. Loss of BRCA1 results in
genomic instability, probably due to an
impaired DNA damage response. It is
therefore likely that BRCA1 suppresses
tumorigenesis by preventing genetic
instability.
Two regions of the BRCA1 protein are
thought to be critical to this function: first,
an N-terminal RING domain that has E3ubiquitin ligase activity that is potentiated
through its interaction with BARD1; and
second, the C-terminal BRCT domain
that mediates the specific interaction
with the phosphorylated form of DNA
repair factors (Figure 1) (Huen et al.,
2010). However, the mechanism by which
these two regions contribute to tumor
suppression has not been clarified. Two
recent papers provide this critical informa-
tion (Shakya et al., 2011; Drost et al., 2011
[this issue of Cancer Cell]). In addition the
conclusionsdrawn from thesenewstudies
have potential clinical implications for the
treatment of patients with breast cancer
in which BRCA1 has been mutated.
Using mice, Shakya et al. (2011)
dissected the function of the RING
domain associated ubiquitin ligase
activity and the BRCT domain. In partic-
ular they assessed how these two regions
of BRCA1 contributed to embryonic
development (the homozygous Brca1
null mutation is embryonic lethal) and
tumor suppression. The E3 ligase activityof the RING domain has previously been
implicated in the DNA damage response
(Ruffner et al., 2001) and more recently
in the maintenance of heterochromatin
(Zhu et al., 2011). Furthermore, human
cancer predisposing mutations often
clustered in this region with some, such
as BRCA1C61G, abrogating E3 ubiquitin
ligase activity. Cellular studies have
shown that BRCA1 localized to DNA
damage induced foci which also con-
tained polyubiquitinated substrates
(Morris and Solomon, 2004). Though
compelling, these lines of evidence are
correlative and lack genetic evidence
directly linking the E3 ubiquitin ligase
activity to the role of BRCA1 in DNA repair
and in tumor suppression. Shakya et al.
(2011) therefore engineered a point muta-
tion within the RING finger domain of
BRCA1. This Brca1I26A mutation results
in the loss of the E3 ligase activity of
BRCA1 but does not compromise either
the stability of the protein or its interaction
with BARD1. Previous work from theecember 13, 2011 ª2011 Elsevier Inc. 693
Figure 1. Domain Organization and Structure of
BRCA1
Top, Schematic representation of the BRCA1 polypeptide
showing the N-terminal RING domain and the C-terminal
BRCT domains. Point mutations discussed here are indi-
cated.
Bottom, The NMR structure of the BRCA1/BARD1 dimer-
ized RING domains (Brzovic et al., 2001). The relevant
key amino acids discussed here are highlighted.
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ES cells carrying this mutation were
not DNA damage sensitive and were
competent at DNA double strand
break repair through homologous
recombination (Reid et al., 2008). To
complete their analysis, they have
now transmitted the mutation into
the mouse germline. Homozygous
Brca1I26A animals were born normally
at expected Mendelian ratios and
were not cancer-prone, although
they did display moderate male infer-
tility. To determine if the E3 ligase
activity of BRCA1 had a tumor
suppression function independent of
DNA repair, the authors introduced
this mutation into three different
cancer-prone genetic backgrounds
and found no additive influence.
Given the correlative evidence
described earlier, the key observation
that BRCA1 E3 ligase activity was dis-
pensible for both DNA repair
and tumor suppression is a complete
surprise.
To test the function of the BRCT
domain, Shakya et al. (2011) intro-
duced a point mutation (S1598F, cor-
responding to S1655F in humanBRCA1). This was predicted to disrupt
domain function since the residue should
be critical for recognition of phosphory-
lated DNA damage response factors. In
contrast to the I26 mutation, the authors
found residue S1598 to be crucial for
both development and cancer suppres-
sion. Although both mutations were engi-
neered into two regions that often carry
breast-/ovarian cancer-associated muta-
tions, it is important to realize that I26A
has not been identified as a germline
mutation in BRCA1 patients.
In this issue of Cancer Cell, Drost et al.
(2011) engineered mice carrying a well
known breast cancer associatedmutation
of BRCA1C61G. This amino acid substitu-
tion in the RING domain is known to inac-
tivate E3 ligase activity but also to disrupt
the RING-RING interaction with BARD1
(Figure 1) (Brzovic et al., 2001; Ruffner
et al., 2001). The consequences of this
point mutation in mice contrast with what
Shakya et al. (2011) observed. Homozy-
gous mice were not born because of
developmental delay and attrition early in
development. Drost et al. (2011) then
introduced Brca1C61G into the KB1P
mouse model of mammary tumor devel-694 Cancer Cell 20, December 13, 2011 ª20opment in which both Brca1 and p53 are
specifically deleted in themammary tissue
(K14Cre;Brca1F/C61G;p53F/F). The latency
and nature of mammary tumors devel-
oped by mice carrying one allele of
Brca1C61G and one null allele was similar
to those carrying two Brca1 null alleles.
However, these cancers showed different
responses to two classes of chemothera-
peutic agents: cisplatin, a crosslinking
agent, and Olaparib, a PARP inhibitor.
An important development in treating
tumors with BRCA1 mutations was the
demonstration that pharmacological inhi-
bition of poly ADP ribosylase activity
(PARP inhibitors) results in potent cyto-
toxicity of BRCA1-deficient cancer cells.
This class of drug has been shown to
result in striking clinical responses in
BRCA1 mutant patients with advanced
breast cancer (Fong et al., 2009; Tutt
et al., 2010). PARP-facilitated base exci-
sion repair can compensate for the defect
in DNA repair caused by BRCA1 defi-
ciency. Removing this backup by PARP
inhibition would therefore lead to the
accumulation of unrepaired endogenous
DNA damage and subsequently cell
death. Drost et al. (2011) adoptively trans-11 Elsevier Inc.ferred tumors carrying the wild-type
Brca1, Brca1C61G, or Brca1 null into
syngeneic recipients; they then
treated the mice with either cisplatin
or olaparib. They noted that the
Brca1C61G tumors responded poorly
to cisplatin and olaparib treatments
compared to Brca1 null tumors. The
Brca1 null tumors did not develop
resistance to cisplatin and were
undetectable while being treated
with olaparib, whereas the Brca1C61G
group developed resistance to both
drugs. Importantly, they found that
the cisplatin-resistant Brca1C61G
tumors were cross-resistant to ola-
parib but responded to
the bifunctional alkylator nimustine,
which preferentially generates inter-
strand crosslinks similar to cisplatin-
sentitive tumors. To extend on their
findings, Drost et al. (2011) looked,
in more detail, at the DNA repair
defect in tumors deficient for Brca1
or carrying the Brca1C61G mutation.
They found that both groups of
tumors developed similar levels of
DNA damage following treatment
with the crosslinking agent cisplati-
num. However, onlyBrca1 null tumorsaccumulated DNA damage following
treatment with olaparib. The difference in
response to treatment and development
of resistance may be due to residual
DNA repair activity of the BRCA1C61G
protein. Finally, they excluded that rever-
sion of the Brca1C61G mutation was
responsible for drug resistance.
Cumulatively, these two studies
provide new genetic insight into BRCA1
tumor suppressor activity, with clinical
implications. The first salient conclusion
is that the RING domain-associated E3
ligase is dispensable for both DNA repair
and tumor suppression—an important
fact that allows the field to move on.
Second, some mutations within the
RING domain compromise tumor sup-
pressor function through impaired DNA
repair. This could be due to the impact
of such a mutation on BRCA1’s interac-
tion with BARD1. The disruption of
interaction between BRCA1 and BARD1
may affect the stability of both proteins
or suggest functions of the BRCA1-
BARD1 interaction independent of E3
ligase activity. Perhaps themost provoca-
tive finding is that tumors carrying the
RING-associated mutation rapidly
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Previewsacquire resistance to cisplatin and PARP
inhibitors. Aside from allowing clinicians
to anticipate such a response, if a patient
should carry a tumor with this class of
mutation, what could be the possible
mechanism that gives rise to this? We
do not know; however it does seem that
these tumors tolerate the accumulation
of DNA damage or that they are able to
switch on compensatory repair pathways
that require a BRCA1 function that is not
affected by this mutation, or a combina-
tion of both. All in all, these studies
provide new murine models for mutant
BRCA1-driven breast carcinogensis,
providing intriguing new results and an
excellent platform for future studies.REFERENCES
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In this issue of Cancer Cell, Snuderl and coworkers demonstrate intratumoral genetic heterogeneity in glio-
blastoma based on in situ amplification of distinct genomic loci within individual cells in a mutually exclusive
pattern. These findings may herald trouble for current targeted therapies but provide insights for future treat-
ment strategies.Glioblastoma multiforme (GBM) is among
the most lethal of all human cancers with
a median survival of about 14 months
despite aggressive surgical resection
and adjuvant chemotherapy with radia-
tion (Stupp et al., 2005). Nevertheless,
the clinical course of some GBM patients
can be highly variable, which may, in part,
be attributable to the recent identification
of a least four molecular subtypes of GBM
(Verhaak et al., 2010). These molecular
subtypes, however, do not explain the
diverse array of pathological findings
within any given GBM including morpho-
logically distinct tumor cells with various
patterns of growth (e.g., bulky tumor to
single cell invasion along white mater
tracks) and variable effects on the host
tissue that are pathognomonic of thedisease and responsible for the designa-
tion ‘‘multiforme’’ (Bailey and Cushing,
1926).
One potential explanation for the diver-
sity of intratumoral findings is that the
phenotype of the GBM clonogenic or
stem cell is plastic and variable, affected
by both intracellular (e.g., stochastic) and
extracellular (e.g., microenvironmental)
stimuli. Asa result, the variablephenotypes
may represent different degrees of aber-
rant differentiation of a cancer stem cell.
A more complex and therapeutically chal-
lenging explanation for the clinical and
pathologic variability of GBMs, however,
is that we are actually dealing with
‘‘different tumors’’ within a given patient.
The term ‘‘tumor heterogeneity’’ can be
defined as the presence of subclones ofcells, within a given tumor, with different
genetic aberrations that mediate diver-
gent biology that define the natural history
of that particular tumor (Navin et al., 2011;
Yachida et al., 2010). Although not a
new idea, the recent advent of high-
throughput molecular and genetic meth-
odologies has begun to explore the nature
of this phenomenon. To that end, several
recent papers have used high-resolution
chromosomal copy number analysis and
next generation sequencing to show
a range of genetically divergent tumor
cell clones within leukemia (Stephens
et al., 2011), breast cancer (Navin et al.,
2011), and pancreatic cancer (Yachida
et al., 2010).
In this issue ofCancer Cell, Snuderl and
co-workers (2011) use fluorescenceecember 13, 2011 ª2011 Elsevier Inc. 695
